TN-10 Extension Study—Teplizumab following Stage 3 Type 1 Diabetes Diagnosis in Participants from the TN-10 Trial

Authors
Category Primary study
ConferenceDiabetes
Year 2025
This article has no abstract
Epistemonikos ID: 056ad651a934f261a7eae87d8aae5ae225df24cc
First added on: May 18, 2026